Loberamisal

洛贝米柳

Report date: 2026/04/15 20:02:38
NME

Base Information

Drug NameLoberamisal
Drug Alias Name洛贝米柳Y-3ZL006-05
ClassificationSmall molecules
Mechanisms of ActionDisks large homolog 4 modulatorsNitric oxide synthase modulatorsGamma-aminobutyric acid A receptor agonists
TargetsDisks large homolog 4Nitric oxide synthaseGamma-aminobutyric acid A receptor
Therapy Area/IndicationsLiver DysfunctionIschemic StrokeDepression +[5] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesMainland China
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesYantai Yene Pharma Co LtdNeuroDawn Pharmaceutical Co Ltd
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesChina Medical System Holdings LtdNeuroDawn Pharmaceutical Co LtdYantai Yene Pharma Co Ltd
Inactive CompaniesN/A
Active IndicationsLiver DysfunctionIschemic StrokeDepression +[5] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A